Epileptic Seizures Treatment Global Market Report 2024

The epileptic seizures treatment market size has grown strongly in recent years. It will grow from $3.21 billion in 2023 to $3.42 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to several factors, including advancements in antiepileptic drugs (AEDs), research breakthroughs in epilepsy treatment, increased awareness and education about the condition, expanded access to healthcare services, and a rise in the prevalence of epilepsy.

The epileptic seizures treatment market size is expected to see strong growth in the next few years. It will grow to $4.43 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to several factors, including precision medicine approaches, emerging therapeutic modalities, the adoption of telemedicine and remote monitoring technologies, healthcare integration and multidisciplinary care models, and regulatory support and incentives. Major trends expected during this period include the advancement of personalized medicine, integration of digital health solutions into epilepsy management, emergence of novel therapeutic modalities, increased focus on addressing comorbidities and improving quality of life for patients, and continued regulatory support and efforts to improve market access for epilepsy treatments.

The increasing incidence of epilepsy is anticipated to drive the growth of the market for treating epileptic seizures in the future. Epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures, stems from abnormal electrical activity in the brain, leading to various symptoms such as convulsions, loss of consciousness, and sensory or behavioral disturbances. Factors contributing to the rising prevalence of epilepsy include improved survival rates among individuals with brain injuries or strokes and a growing elderly population. Effective treatment of epileptic seizures, primarily through antiepileptic drugs (AEDs), can significantly reduce their frequency and severity, thus ensuring patients' daily functioning and overall well-being. For instance, as of February 2024, the World Health Organization reported approximately 50 million people worldwide suffering from epilepsy, with about 5 million new diagnoses annually. Hence, the increasing incidence of epilepsy is fueling the expansion of the market for treating epileptic seizures.

Key players in the epileptic seizures treatment market are innovating to develop alternative treatment solutions, such as cannabis-based medications, particularly for patients unresponsive to traditional antiseizure drugs. Cannabis-based drugs, derived from the cannabis plant, harness the therapeutic properties of cannabinoids to address various medical conditions, including epilepsy, primarily for their anticonvulsant effects. For example, in January 2024, Akumentis Healthcare Ltd. introduced Clasepi, an orally administered cannabis plant-based medication approved by India's Drug Controller General to manage seizures, especially in children with conditions such as Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex. Clasepi, containing minimal tetrahydrocannabinol (THC) content, has shown efficacy in reducing seizures, particularly in cases where conventional treatments have proven ineffective, albeit it's cautioned for individuals allergic to cannabidiol or its constituents.

In March 2022, UCB SA bolstered its presence in the epileptic seizures treatment market by acquiring Zogenix Inc. for approximately $1.9 billion. This strategic move not only expands UCB's revenue potential but also grants access to promising epilepsy treatments, reinforcing its commitment to offering innovative solutions for severe forms of epilepsy such as Dravet syndrome. Zogenix Inc., a US-based biopharmaceutical company specializing in drugs and therapies for rare diseases, particularly rare pediatric epilepsy, thus enhances UCB's portfolio and strengthens its position in addressing the unmet medical needs of epilepsy patients.

Major companies operating in the epileptic seizures treatment market are Pfizer Inc., Johnson & Johnson Service Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Takeda Pharmaceutical Co. Ltd., Medtronic plc, GE HealthCare Technologies Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Dragerwerk AG & Co.KGaA, H. Lundbeck A/S, Apotex Inc., Masimo Corporation, Fisher & Paykel Healthcare Limited, Inspiration Healthcare Group Plc., Phoenix Medical Systems (P) Ltd., Marinus Pharmaceuticals Inc., Alexza Pharmaceuticals Inc., Neurelis Inc., Veriton Pharma.

North America was the largest region in the epileptic seizures treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epileptic seizures treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the epileptic seizures treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Epileptic seizure treatment encompasses medical interventions and therapies aimed at managing and controlling seizures in individuals with epilepsy, a neurological disorder characterized by recurrent and unpredictable seizures. Treatment options may include medications, lifestyle modifications, dietary therapies, and other interventions tailored to each patient's specific needs, with the goal of reducing seizure frequency and severity and improving overall quality of life.

The main types of epileptic seizure treatment include established treatment practices, emerging drugs, and individualized therapies. Treatment practices involve methodologies used by healthcare professionals to manage symptoms, including pharmacological interventions, surgical procedures, and non-pharmacological therapies. These treatments address various seizure types, such as partial, generalized, and unclassified seizures, and can be administered via oral or buccal, nasal, rectal, or parenteral routes. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The epileptic seizures treatment market research report is one of a series of new reports that provides epileptic seizures treatment market statistics, including epileptic seizures treatment industry global market size, regional shares, competitors with an epileptic seizures treatment market share, detailed epileptic seizures treatment market segments, market trends and opportunities, and any further data you may need to thrive in the epileptic seizures treatment industry. This epileptic seizures treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epileptic seizures treatment market consists of revenues earned by entities by providing services, such as medication management, rehabilitation services, diagnostic services, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The epileptic seizures treatment market also includes sales of anti-epileptic drugs, surgical implants, ketogenic diet products, seizure alarms, and vagus nerve stimulators which are used in providing the services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.